The diagnostic performance of [18F]FET PET/MRI versus [18F]FDG PET/MRI for recurrent glioma: a systematic review and meta-analysis

Purpose Our systematic review and meta-analysis aimed to evaluate the diagnostic performance of [18F]FDG PET/MRI vs. [18F]FET PET/MRI for recurrent glioma. Methods We searched for relevant articles in PubMed, Embase, and Web of Science until February 2023. Studies regarding the diagnostic performanc...
Ausführliche Beschreibung

Purpose Our systematic review and meta-analysis aimed to evaluate the diagnostic performance of [18F]FDG PET/MRI vs. [18F]FET PET/MRI for recurrent glioma. Methods We searched for relevant articles in PubMed, Embase, and Web of Science until February 2023. Studies regarding the diagnostic performance of [18F]FET PET/MRI or [18F]FDG PET/MRI in recurrent glioma were included. The quality of each study was assessed using the Quality Assessment of Diagnostic Performance Studies-2 (QUADAS-2) tool. Results A total of nine studies with 310 patients were included in the analysis, the pooled sensitivity, specificity of [18F]FDG PET/MRI in detecting recurrent glioma after definitive treatment were 0.99 (95% CI 0.75–1.00) and 0.62 (95% CI 0.37–0.83), [18F]FET PET/MRI were 0.94 (95% CI 0.81–0.98) and 0.87 (95% CI 0.70–0.95), respectively. The area under curve (AUC) for [18F]FDG PET/MRI and [18F]FET PET/MRI were 0.92 (95% CI 0.89–0.94) and 0.96 (95% CI 0.94–0.97) and there is a statistical difference between the two imaging modalities (Z = 12.433, P < 0.001). Fagan nomogram indicated that when the pre-test probability was set at 50%, the post-test probability for [18F]FDG PET/MRI and [18F]FET PET/MRI could increase to 72 and 88%. Conclusions [18F]FET PET/MRI has a higher AUC compared to [18F]FDG PET/MRI in the detection of tumor recurrence in glioma. However, the results of the meta-analysis were drawn from studies with small samples. Further larger prospective studies in this setting are warranted. Ausführliche Beschreibung